Ngenla ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
78	Hypopituitarism	2

78. Hypopituitarism

---

Clinical trials : 492 /  Drugs : 341 - (DrugBank : 47) / Drug target genes : 45 - Drug target pathways : 100

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05509894 (ClinicalTrials.gov)	November 2023	19/8/2022	Korean Post-marketing Surveillance Ngenla® Pre-filled Pen Injection for the Treatment of Pediatric Patients With Growth Disturbance Due to Insufficient Secretion of Growth Hormone	Post Marketing Surveillance (PMS) Study for Ngenla® Pre-filled Pen in Pediatric Patients Who Have Growth Disturbance Due to Insufficient Secretion of Growth Hormone in Korea	Pediatric Growth Hormone Deficiency	Drug: Ngenla	Pfizer	NULL	Not yet recruiting	3 Years	19 Years	All	565		NULL
2	NCT05602766 (ClinicalTrials.gov)	February 6, 2023	27/10/2022	Ngenla Subcutaneous Injection Special Investigation	Ngenla® Subcutaneous Injection Special Investigation	Growth Hormone Deficiency Without Epiphyseal Closure	Drug: NGENLA (Somatrogon)	Pfizer	NULL	Recruiting	N/A	15 Years	All	229		Japan